Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-Current Assets: 2010-2024

Historic Non-Current Assets for Anika Therapeutics (ANIK) over the last 15 years, with Dec 2024 value amounting to $89.1 million.

  • Anika Therapeutics' Non-Current Assets fell 7.82% to $87.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year decrease of 7.82%. This contributed to the annual value of $89.1 million for FY2024, which is 16.99% down from last year.
  • Anika Therapeutics' Non-Current Assets amounted to $89.1 million in FY2024, which was down 16.99% from $107.3 million recorded in FY2023.
  • Anika Therapeutics' Non-Current Assets' 5-year high stood at $188.2 million during FY2020, with a 5-year trough of $89.1 million in FY2024.
  • Its 3-year average for Non-Current Assets is $125.3 million, with a median of $107.3 million in 2023.
  • As far as peak fluctuations go, Anika Therapeutics' Non-Current Assets soared by 95.24% in 2020, and later plummeted by 40.24% in 2023.
  • Over the past 5 years, Anika Therapeutics' Non-Current Assets (MRY) stood at $188.2 million in 2020, then decreased by 4.90% to $179.0 million in 2021, then rose by 0.32% to $179.6 million in 2022, then plummeted by 40.24% to $107.3 million in 2023, then decreased by 16.99% to $89.1 million in 2024.
  • Its last three reported values are $89.1 million in FY2024, $107.3 million for FY2023, and $179.6 million during FY2022.